This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CARLOS A. LEON, MD
Unidad de Salud Mental Hospital Universitario del Valle Cali, Colombia, South America

Arch Gen Psychiatry. 1978;35(7):905.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—There are relatively few reports as yet in the American literature on the efficacy of clozapine. I am reporting on a three-year case history follow-up of 37 schizophrenic patients (out of an initial cohort of 50) who had participated in a doubleblind, hospital-based drug trial of clozapine vs chlorpromazine for a sixweek period.¹ Clozapine (chloro-methylpiperazinyl-dibenzo-diazepine) is of interest because it is a derivative of the diabenzapines (related to the tricyclic compounds) that has been found to have antipsychotic properties, although pharmacologically it does not behave like a neuroleptic.² It has been shown to be practically free of extrapyramidal effects since it is essentially an anticholinergic.^3,4

The initial report requires expansion since it did not emphasize sufficiently the fact that the clozapine capsules mistakenly contained a dose double that which was initially planned. Hence, the mean daily dosage for both drugs fluctuated around 600 mg. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?